ASCO 2022

MRD: The new standard

clonoSEQ is:

  • The most sensitive FDA-cleared MRD Assay for multiple myeloma, CLL, and ALL
  • CLIA-validated in other lymphoid malignancies
  • Reimbursed by Medicare and major private payers for multiple myeloma, CLL, and ALL
  • Clinically used in all 32 NCCN® Member Institutions
  • Included in clinical practice guidelines for multiple myeloma, CLL, and ALL
  • Supported by a significant and expanding body of evidence
  • Featured in TBD abstracts at the ASCO Congress
  • Widely used, having been performed on >22,000 unique patients to date

For information on ordering clonoSEQ, call us at (888) 552-8988.


Coming soon

Coming soon

Coming soon

Discover clinicians’ real-world experience with clonoSEQ MRD testing

View cases, videos, patient perspectives and more, which illustrate how MRD testing by clonoSEQ may inform clinical decision-making.

Real-World Experience Data

clonoSEQ Product Resources

Learn more about clonoSEQ Assay by downloading these helpful resources:

  • clonoSEQ key publications
  • Talking to your patients about clonoSEQ results
  • HCP Brochure
  • clonoSEQ insurance coverage summary
  • clonoSEQ one-page overview
  • Clinical data summary: CLL MM ALL
  • clonoSEQ clinical reports one pager
  • Adaptive Assist patient support program overview

Connect with Medical Affairs

Request information from a member of our Medical Affairs team.

Adaptive Immune Medicine Platform

Learn how the platform applies our proprietary technologies, computational biology, software and machine learning to read the diverse genetic code of a patient’s immune system and understand precisely how it detects and treats disease in that patient.

Twitter feed Follow us

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). CLL Clonality (ID) Tests will also produce an IGHV status result, which is provided as a CLIA-validated laboratory developed test (LDT) but which has not been cleared or approved by the FDA. Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.